These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10091198)

  • 1. Coronary heart disease in women, randomized clinical trials, HERS and RUTH.
    Barrett-Connor E; Wenger NK; Grady D; Mosca L; Collins P; Kornitzer M; Cox DA; Moscarelli E; Anderson PW
    Maturitas; 1998 Nov; 31(1):1-7. PubMed ID: 10091198
    [No Abstract]   [Full Text] [Related]  

  • 2. A critical European view of the HERS trial.
    Lauritzen C
    Maturitas; 1998 Nov; 31(1):15-9. PubMed ID: 10091200
    [No Abstract]   [Full Text] [Related]  

  • 3. The heart and estrogen/progestin replacement study (HERS).
    Speroff L
    Maturitas; 1998 Nov; 31(1):9-14. PubMed ID: 10091199
    [No Abstract]   [Full Text] [Related]  

  • 4. Postmenopausal hormone replacement therapy in the light of the women's health initiative trial.
    van der Mooren MJ; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):123-4. PubMed ID: 12648855
    [No Abstract]   [Full Text] [Related]  

  • 5. The time has come to stop letting the HERS tale wag the dogma.
    Mendelsohn ME; Karas RH
    Circulation; 2001 Nov; 104(19):2256-9. PubMed ID: 11696459
    [No Abstract]   [Full Text] [Related]  

  • 6. Hormone replacement therapy to prevent coronary events.
    Richard D; Newton WP
    J Fam Pract; 1998 Nov; 47(5):333-4. PubMed ID: 9834761
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
    Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
    JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in postmenopausal hormone therapy use since 1988.
    Kim JK; Alley D; Hu P; Karlamangla A; Seeman T; Crimmins EM
    Womens Health Issues; 2007; 17(6):338-41. PubMed ID: 17936641
    [No Abstract]   [Full Text] [Related]  

  • 9. What pharmacists need to know about the women's health initiative estrogen plus progestin trial.
    Saseen JJ; Hansen LB
    Am J Health Syst Pharm; 2003 Feb; 60(3):281-4. PubMed ID: 12613239
    [No Abstract]   [Full Text] [Related]  

  • 10. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?
    Machens K; Schmidt-Gollwitzer K
    Hum Reprod; 2003 Oct; 18(10):1992-9. PubMed ID: 14507812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy should not be used as secondary prevention of coronary heart disease.
    Barbour MM
    Pharmacotherapy; 2000 Sep; 20(9):1021-7. PubMed ID: 10999492
    [No Abstract]   [Full Text] [Related]  

  • 12. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study.
    Herrington DM
    Ann Intern Med; 1999 Sep; 131(6):463-6. PubMed ID: 10498564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the null hypothesis--do the HERS results disprove the estrogen/coronary heart disease hypothesis?
    Blumenthal RS; Zacur HA; Reis SE; Post WS
    Am J Cardiol; 2000 Apr; 85(8):1015-7. PubMed ID: 10760346
    [No Abstract]   [Full Text] [Related]  

  • 14. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S
    Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HRT: forever or never?
    Corson SL
    Int J Fertil Womens Med; 2002; 47(4):150-1. PubMed ID: 12199410
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormone replacement therapy for prevention of coronary heart disease: current evidence.
    Khurana PS; Khurana C; Hsia J
    Curr Atheroscler Rep; 2001 Sep; 3(5):399-403. PubMed ID: 11487451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women.
    Fugère P; Scheele WH; Shah A; Strack TR; Glant MD; Jolly E
    Am J Obstet Gynecol; 2000 Mar; 182(3):568-74. PubMed ID: 10739509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective estrogen receptor modulators and postmenopausal women's health.
    Hol T; Cox MB; Bryant HU; Draper MW
    J Womens Health; 1997 Oct; 6(5):523-31. PubMed ID: 9356975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N;
    JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
    Col NF; Pauker SG; Goldberg RJ; Eckman MH; Orr RK; Ross EM; Wong JB
    Arch Intern Med; 1999 Jul; 159(13):1458-66. PubMed ID: 10399897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.